Nail loss might represent a new, reversible, adverse event associated with teriflunomide treatment. It shares close analogies with hair loss and thinning, known adverse events of teriflunomide. MS specialists should be aware of this possibility and evaluate treatment discontinuation.
Nail loss after teriflunomide treatment: a new potential adverse event
MANCINELLI, LUCA;AMERIO, Paolo;DI IOIA, MARIA;DI TOMMASO, VALERIA;DE LUCA, Giovanna;ONOFRJ, Marco;
2017-01-01
Abstract
Nail loss might represent a new, reversible, adverse event associated with teriflunomide treatment. It shares close analogies with hair loss and thinning, known adverse events of teriflunomide. MS specialists should be aware of this possibility and evaluate treatment discontinuation.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mancinelli_Multiple Sclerosis and Related Disorders_2017.pdf
Solo gestori archivio
Descrizione: Articolo principale
Tipologia:
Documento in Post-print
Dimensione
279.47 kB
Formato
Adobe PDF
|
279.47 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
